2022
Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder
Holmes S, Asch R, Davis M, DellaGioia N, Pashankar N, Gallezot J, Nabulsi N, Matuskey D, Sanacora G, Carson R, Blumberg H, Esterlis I. Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder. Biological Psychiatry 2022, 93: 1099-1107. PMID: 36764853, PMCID: PMC10164841, DOI: 10.1016/j.biopsych.2022.10.018.Peer-Reviewed Original ResearchConceptsMajor depressive disorderMetabotropic glutamate receptor 5Glutamate receptor 5MGluR5 availabilityBipolar disorderPositron emission tomographyHC groupDepressive disorderReceptor 5Emission tomographyHealthy control individualsPossible treatment targetsGlutamate transmissionBD depressionTreatment strategiesBD groupMGluR5Depressive symptomsNovel treatmentsCognitive alterationsTreatment targetsSynaptic plasticityControl individualsAccurate diagnosisSignificant negative correlation
2011
1H-[13C]-Nuclear Magnetic Resonance Spectroscopy Measures of Ketamine's Effect on Amino Acid Neurotransmitter Metabolism
Chowdhury GM, Behar KL, Cho W, Thomas MA, Rothman DL, Sanacora G. 1H-[13C]-Nuclear Magnetic Resonance Spectroscopy Measures of Ketamine's Effect on Amino Acid Neurotransmitter Metabolism. Biological Psychiatry 2011, 71: 1022-1025. PMID: 22169441, PMCID: PMC3660962, DOI: 10.1016/j.biopsych.2011.11.006.Peer-Reviewed Original ResearchConceptsMedial prefrontal cortexSubanesthetic dosesAcute effectsNeurotransmitter cyclingMagnetic resonance spectroscopy measuresMPFC of ratsPotential physiological processesAntidepressant-like propertiesSaline-treated animalsAmino acid neurotransmittersHippocampus of ratsDose of ketamineEffects of ketamineGlial energy metabolismMPFC levelsGlutamate releaseKetamine effectsΓ-aminobutyric acidGlial metabolismKetaminePrefrontal cortexEnrichment of glutamateVivo studiesEnergy metabolismRats
2008
Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole
Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, Sanacora G. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Molecular Psychiatry 2008, 15: 501-511. PMID: 18825147, PMCID: PMC3347761, DOI: 10.1038/mp.2008.106.Peer-Reviewed Original ResearchMeSH KeywordsAcetatesAnimalsAvoidance LearningBehavioral SymptomsDepressionDisease Models, AnimalFood PreferencesGene Expression RegulationGlial Fibrillary Acidic ProteinGlutamic AcidIsotopesMagnetic Resonance SpectroscopyMaleNeurogliaNeuroprotective AgentsPrefrontal CortexRadionuclide ImagingRatsRats, Sprague-DawleyRiluzoleRNA, MessengerStatistics, NonparametricStress, PsychologicalSucroseSweetening AgentsConceptsChronic unpredictable stressPrefrontal cortexGlial dysfunctionGlial functionBehavioral deficitsDrug riluzoleOpen-label clinical trialMRNA expressionAmino acid neurotransmissionAntidepressant drug developmentDepressive-like behaviorPathophysiology of depressionEffects of riluzoleGlial cell metabolismMajor depressive disorderRat prefrontal cortexGFAP mRNA expressionProtein mRNA expressionNeurotransmitter system abnormalitiesGlia pathologyGlial pathologyRiluzole treatmentAntidepressant actionChronic treatmentGlutamate release
2000
A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression
Berman R, Narasimhan M, Sanacora G, Miano A, Hoffman R, Hu X, Charney D, Boutros N. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biological Psychiatry 2000, 47: 332-337. PMID: 10686268, DOI: 10.1016/s0006-3223(99)00243-7.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationTranscranial magnetic stimulationMajor depressionHDRS scoresMagnetic stimulationEfficacy of rTMSHamilton Depression Rating Scale scoresActive repetitive transcranial magnetic stimulationRandomized double-blind mannerTreatment-resistant major depressionDepression Rating Scale scoresDouble-blind mannerTreatment-resistant patientsRandomized clinical trialsRating Scale scoresMotor threshold determinationActive treatmentSham treatmentTreatment trialsClinical trialsTreatment resistanceMean decreaseDepressive symptomsControl groupScale score